NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) Following Faster KT 621 Trial Progress Still Looks Modestly Undervalued
Kymera Therapeutics (KYMR) has finished enrolling patients earlier than planned in its global BROADEN2 Phase 2b trial of KT-621 for moderate to severe atopic dermatitis. As a result, the expected timeline for topline data has been moved forward.
See our latest analysis for Kymera Therapeutics.
The earlier KT-621 enrollment completion comes after a period of strong share price momentum for Kymera Therapeutics, with a 30 day share price return of 54.81% and a 1 year total shareholder return of...